ProCE Banner Activity

BANNER Study: Broadly Neutralizing Antibody VH3810109 in People With HIV Naive to Treatment

Slideset Download
Conference Coverage

The broadly neutralizing antibody VH3810109, administered by a single IV infusion, displayed antiviral efficacy and was well tolerated in people with HIV naive to treatment.

Released: November 04, 2022

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

ViiV Healthcare